

BIOINFORMANT

Global Cord Blood and Tissue Banking Industry Report



**1ST AND ONLY MARKET RESEARCH FIRM TO
SPECIALIZE IN THE STEM CELL INDUSTRY**

TABLE OF CONTENTS

1.	REPORT OVERVIEW	12	
1.1	Statement of the Report	12	
1.2	Executive Summary	15	
1.3	Introduction	16	
1.3.1	Cord Blood: An Alternative Source for Hematopoietic Stem Cell Transplantation (HSCT)	17	
1.3.2	Utilization of Cord Blood Cells within Clinical Trials	17	
1.3.3	Challenges of Cord Blood Banking	17	
1.3.4	Emerging Technologies that Support the Financial Sustainability of Cord Blood Banks	18	
1.3.4.1	Strategic Opportunities that Improve the Financial Stability of Cord Blood Banks	19	
1.3.4.2	Scope for Companion Products for Cord Blood Banks	20	
1.3.5	Evolving Landscape for Cord Blood and Tissue Banking, by Geography	20	
1.3.6	Product and Service Extensions Offered by Cord Blood Banks	21	
1.4	Current Status of the Cord Blood and Tissue Banking Industry	22	
1.4.1	Diversification of Cord Blood and Tissue (CBT) Products & Services	22	
1.4.2	Pairing with Genetic Testing Services	23	
1.4.3	Pairing with Fertility and Assisted Reproduction Services	23	
1.4.4	Cord Blood and Tissue Banking Industry Consolidation	24	
1.4.5	Cord Blood Banks as Integrated Therapeutic Companies	25	
2.	CORD BLOOD & CORD BLOOD BANKING: AN OVERVIEW	26	
2.1	Cord Blood, Cord Tissue, and Perinatal Stem Cell Banking	27	
2.1.1	Public Cord Blood Banks	27	
2.1.1.1	Economic Model of Public Cord Blood Banks	28	
2.1.1.2	Cost Analysis for Public Banks	30	
2.1.1.3	Relationship between Costs and Release Rates for Cord Blood Units (CBUs)	30	
2.1.2	Private Cord Blood Banks	31	
2.1.2.1	Cost Analysis for Private Cord Blood Banks	31	
2.1.2.2	Economic Model of Private Cord Blood Banks	32	
2.1.3	Hybrid Cord Blood Banks	33	
2.2	Global Leaders within the Private Cord Blood and Tissue Banking Market	33	
2.2.1	Comparing Cord Blood Banks	36	
2.2.2	Leading Cord Blood Banks within the U.S.	37	
2.2.3	Breakdown of Public, Private and Hybrid Banks within the U.S.	40	
2.3	Percent Share of Parents Storing Cord Blood by Country/Region	40	
2.4	Pricing for Processing and Storage at Leading Cord Blood and Tissue Banks	41	
2.4.1	Rates Per Cord Blood Unit (CBU) within the U.S. and Europe	42	
2.5	Annual Cord Blood Revenues for Leading Cord Blood Banks	43	
3.	CORD BLOOD BANK ACCREDITATIONS	45	
3.1	American Association of Blood Banks (AABB)	45	
3.2	Foundation for the Accreditation of Cellular Therapy (FACT)	45	
3.3	FDA Registration	45	
3.4	FDA Biologics License Application (BLA) License	46	
3.5	Investigational New Drug (IND) for Cord Blood	46	
3.6	Human Tissue Authority (HTA)	46	
3.7	Therapeutic Goods Act (TGA) in Australia	46	

3.8	International NetCord Foundation	47
3.9	AABB Accredited Cord Blood Facilities	47
3.10	FACT Accreditation for Cord Blood Banks	50
4.	APPLICATIONS OF CORD BLOOD CELLS	51
4.1	Hematopoietic Stem Cell Transplantations with Cord Blood Cells	51
4.2	Umbilical Cord Cells in Regenerative Medicine	53
5.	CORD BLOOD PROCESSING TECHNOLOGIES	55
5.1	The Process of Separation	55
5.1.1	PrepaCyte-CB	56
5.1.2	Advantages of PrepaCyte-CB	57
5.1.3	Treatment Outcomes with PrepaCyte-CB	57
5.1.4	Hetastarch (HES)	58
5.1.5	AutoXpress (AXP)	58
5.1.6	SEPAX	59
5.1.7	Plasma Depletion Method (MaxCell Process)	60
5.1.8	Density Gradient Method	60
5.2	Comparative Merits of Different Processing Methods	61
5.2.1	Early-Stage HSC Recovery by Technologies	62
5.2.2	Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood	63
5.2.3	Late-Stage Recovery of HSCs from Cord Blood	64
5.3	HSC (CD45+) Recovery	64
5.4	Days to Neutrophil Engraftment by Technology	65
5.5	Anticoagulants used in Cord Blood Processing	66
5.5.1	Type of Anticoagulant and Cell Recovery Volume	67
5.5.2	Percent Cell Recovery by Sample Size	68
5.5.3	TNC Viability by Time Taken for Transport and Type of Anticoagulant	69
5.6	Cryopreservation of Cord Blood Cells	70
5.7	Bioprocessing of Umbilical Cord Tissue (UCT)	72
5.8	A Proposal to Improve the Utilization Rate of Banked Cord Blood	73
6.	CORD BLOOD CLINICAL TRIALS, SCIENTIFIC PUBLICATIONS & NIH FUNDING	76
6.1	Cord Blood Cells for Research	76
6.2	Cord Blood Cells for Clinical Trials	77
6.2.1	Number of Clinical Trials involving Cord Blood Cells	78
6.2.2	Number of Clinical Trials using Cord Blood Cells by Geography	79
6.2.3	Number of Clinical Trials by Study Type	80
6.2.4	Number of Clinical Trials by Study Phase	81
6.2.5	Number of Clinical Trials by Funder Type	82
6.2.6	Clinical Trials Addressing Indications in Children	83
6.2.7	Select Three Clinical Trials Involving Children	84
6.2.7.1	Sensorineural Hearing Loss (NCT02038972)	85
6.2.7.2	Autism Spectrum (NCT02847182)	85
6.2.7.3	Cerebral Palsy (NCT01147653)	85
6.2.8	Clinical Trials for Neurological Diseases using Cord Blood and Cord Tissue	86
6.2.9	Umbilical Cord Blood (UCB) for Diabetes	87
6.2.10	Umbilical Cord Blood (UCB) in Cardiovascular Clinical Trials	88

6.2.11	Cord Blood Cells for Auto-Immune Diseases in Clinical Trials	88
6.2.12	Cord Tissue Cells for Orthopedic Disorders in Clinical Trials	89
6.2.13	Cord Blood Cells for Other Indications in Clinical Trials	90
6.3	Major Diseases Addressed by Cord Blood within Clinical Trials	91
6.4	Clinical Trials using Cord Tissue-Derived MSCs	91
6.5	Ongoing Clinical Trials using Cord Tissue	93
6.5.1	Cord Tissue-Based Clinical Trials by Geography	93
6.5.2	Cord Tissue-Based Clinical Trials by Phase	94
6.5.3	Cord Tissue-Based Clinical Trials by Sponsor Type	95
6.5.4	Companies Sponsoring Trials using Cord Tissue-Derived MSCs	96
6.6	Wharton's Jelly-Derived MSCs in Clinical Trials	97
6.6.1	Wharton's Jelly-Based Clinical Trials by Phase	97
6.6.2	Companies Sponsoring Wharton's Jelly-Based Clinical Trials	98
6.7	Clinical Trials Involving Cord Blood Expansion Studies	99
6.7.1	Safe and Feasible Expansion Protocols	99
6.7.2	List of Clinical Trials involved in the Expansion of Cord Blood HSCs	100
6.7.3	Expansion Technologies	105
6.8	Scientific Publications on Cord Blood	107
6.9	Scientific Publications on Cord Tissue	108
6.10	Scientific Publications on Wharton's Jelly-Derived MSCs	109
6.11	Published Scientific Papers on Cord Blood Cell Expansion	110
6.12	NIH Funding for Cord Blood Research	111
7.	PARENTAL AWARENESS & ATTITUDES TOWARDS CORD BLOOD BANKING	112
7.1	Factors Affecting Undecided Expectant Parents	112
7.2	Cord Blood Banks Known by Expectant Parents (Brand Recognition)	113
7.3	Factors Influencing Parental Choice of a Cord Blood Bank	114
8.	CORD BLOOD TRANSPLANTATION	115
8.1	Comparisons of Cord Blood versus Other Allograft Sources	116
8.1.1	Major Indications for HSCT within the U.S.	117
8.1.2	Trends in Allogeneic (Donor) HSCT within the U.S. by Recipient Age	118
8.1.3	Trends in Autologous (Patient-Derived) HSCT within the U.S. by Recipient Age	119
8.2	Breakdown of HSCT by Cell Source within Adult Patients	120
8.2.1	HSCTs by Cell Source within Pediatric Patients	121
8.3	Allogeneic HSCTs by Cell Source	122
8.3.1	Unrelated Donor Allogeneic HSCTs in Patients Under 18 Years	123
8.4	Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity	124
8.4.1	Likelihood of Finding an Unrelated Cord Blood Unit for Patients Under 20 Years	125
8.5	Probability of Using a Newborn's Cord Blood	126
8.6	Cord Blood Utilization Trends	127
8.7	Number of Cord Blood Donors Worldwide	128
8.7.1	Number of CBUs Stored Worldwide	129
8.7.2	Number of CBUs, PBSCs and BMCs Shipped	131
8.7.3	Cord Blood Donors by Geography	133
8.7.3.1	Public Cord Blood Units Stored in Different Geographies	134
8.7.3.2	Number of Donors by HLA Typing	135
8.7.4	Searches Made by Transplant Patients for Donors/CBUs	136

8.7.5	Types of CBU Shipments (Single/Double/Multi)	137
8.7.6	TNC Count of CBUs Shipped for Children and Adult Patients	138
8.7.7	Shipment of Multiple CBUs	139
8.7.8	Percent Supply of CBUs for National and International Patients	140
8.7.9	Decreasing Rates of CBU Utilization	141
8.8	Top Ten Countries for Cord Blood Donation	142
8.8.1	HLA Typed Cord Blood Units (CBUs) by Continent	143
8.8.2	TNC Percentage of Banked Cord Blood Units (CBUs)	144
8.8.3	Total Number of CBUs, HLA-Typed Units by Country	145
8.9	Cord Blood Export/Import by E.U. Member States	152
8.9.1	Number of Donors and CBUs in Europe	153
8.9.2	Number of Exports/Imports of Cord Blood Units (CBUs) within E.U.	154
8.10	Global Exchange of Cord Blood Units	155
9.	CORD BLOOD CELLS AS CELLULAR THERAPEUTICS	158
9.1	MSCs from Cord Blood and Cord Tissue	158
9.1.1	Potential Neurological Applications of Cord Blood-Derived Cells	159
9.1.2	Cord Tissue-Derived MSCs for Therapeutic Use	161
9.1.2.1	Indications Targeted by Umbilical Cord Tissue (UCT) MSCs in Clinical Trials	162
9.2	Current Consumption of Cord Blood Units by Clinical Trials	162
9.3	Leading Cord Blood Stem Cell Treatments within Clinical Trials	164
9.3.1	Acquired Hearing Loss (NCT02038972)	164
9.3.2	Autism (NCT02847182)	165
9.3.3	Cerebral Palsy (NCT03087110)	165
9.3.4	Hypoplastic Left Heart Syndrome (NCT01856049)	165
9.3.5	Type 1 Diabetes (NCT00989547)	166
9.3.6	Psoriasis (NCT03765957)	166
9.3.7	Parkinson's Disease (NCT03550183)	166
9.3.8	Signs of Aging (NCT04174898)	167
9.3.9	Stroke (NCT02433509)	167
9.3.10	Traumatic Brain Injury (NCT01451528)	167
10.	MARKET ANALYSIS: MARKET SIZE, SEGMENTATION, AND FUTURE FORECASTS	168
10.1	Cord Blood and Tissue Banking Market Size: Public vs. Private Banking	170
10.2	Cord Blood and Tissue Banking Market Size: By Indication	171
11.	PROFILES OF CORD BLOOD BANKS WORLDWIDE	173
11.1	AllCells	173
11.1.1	Whole Blood	173
11.1.2	Leukopak	174
11.1.3	Mobilized Leukopak	174
11.1.4	Bone Marrow	174
11.1.5	Cord Blood	175
11.2	AlphaCord LLC	175
11.2.1	NextGen Collection System	175
11.3	Americord Registry, Inc.	176
11.3.1	Cord Blood 2.0	176
11.3.2	Cord Tissue	176

11.3.3	Placental Tissue 2.0	177	
11.4	Be The Match	178	
11.4.1	Hub of Transplant Network	181	
11.4.2	Partners of Be The Match	181	
11.4.3	Allogeneic Cell Sources in Be The Match Registry	182	
11.4.4	Likelihood of a Matched Donor on Be The Match by Ethnic Background	183	
11.5	Biocell Center Corporation	186	
11.5.1	Chorionic villi after Delivery	186	
11.5.2	Amniotic Fluid and Chorionic Villi during Pregnancy	186	
11.6	BioEden Group, Inc.	187	
11.6.1	Differences between Tooth Cells and Umbilical Cord Cells	187	
11.7	Biovault Family	188	
11.7.1	Personalized Cord Blood Processing	188	
11.8	Cell Care	189	
11.9	Cells4Life Group, LLP	190	
11.9.1	Cells4Life's pricing	190	
11.9.2	TotiCyte Technology	191	
11.9.3	Cord Blood Releases	191	
11.10	Cell-Save	192	
11.11	Center for International Blood and Marrow Transplant Research (CIBMTR)	193	
11.11.1	Global Collaboration	193	
11.11.2	Scientific Working Committees	193	
11.11.3	Medicare Clinical Trials and Studies	194	
11.11.4	Cellular Therapy	194	
11.12	Cord Blood Center Group	198	
11.12.1	Cord Blood Units Released	198	
11.13	Cordlife Group, Ltd.	201	
11.13.1	Cordlife's Cord Blood Release Track Record	201	
11.14	Core23 Biobank	204	
11.15	Cord Blood Registry (CBR)	205	
11.16	Cordlife Group, Ltd.	207	
11.17	CordVida	208	
11.18	Crioestaminal	209	
11.18.1	Cord Blood Transplantation in Portugal	209	
11.19	Cryo-Cell International, Inc.	210	
11.19.1	Processing Method	210	
11.19.2	Financial Results of the Company	210	
11.19.3	Cryo-Cell International's Pricing	212	
11.20	CryoHoldco	213	
11.21	Cryoviva Biotech Pvt. Ltd	214	
11.22	European Society for Blood and Bone Marrow Transplantation (EBMT)	214	
11.22.1	EBMT Transplant Activity	215	
11.23	FamiCord Group	216	
11.24	GeneCell International	217	
11.25	Global Cord Blood Corporation (GCBC)	218	
11.25.1	The Company's Business	218	
11.26	HealthBaby Hong Kong	220	
11.26.1	BioArchive System Service Plan	220	

11.26.2	MVE Liquid Nitrogen System	220
11.27	HEMAFUND	221
11.28	Insception Lifebank	221
11.29	LifebankUSA	222
11.29.1	Placental Banking	222
11.30	LifeCell International Pvt. Ltd.	223
11.31	MiracleCord, Inc.	224
11.32	Maze Cord Blood Laboratories	225
11.33	New England Cord Blood Bank, Inc.	226
11.34	New York Cord Blood Center (NYBC)	227
11.34.1	Products	227
11.34.2	Laboratory Services	227
11.35	PacifiCord	229
11.35.1	FDA-Approved Sterile Collection Bags	229
11.35.2	AXP Processing System	229
11.35.3	BioArchive System	229
11.36	ReeLabs Pvt. Ltd.	230
11.37	Smart Cells International, Ltd.	231
11.38	Stem Cell Cryobank	232
11.39	StemCyte, Inc.	233
11.39.1	StemCyte Sponsored Clinical Trials	233
11.39.1.1	Spinal Cord Injury Phase II	233
11.39.1.2	Other Trials	233
11.40	Transcell Biolife	234
11.40.1	ScellCare	234
11.40.2	ToothScell	234
11.41	ViaCord	235
11.42	Vita 34 AG	236
11.43	World Marrow Donor Association (WMDA)	237
11.43.1	Search & Match Service	237
11.44	Worldwide Network for Blood & Marrow Transplantation (WBMT)	239

INDEX OF FIGURES

FIGURE 2.1:	Profit Margins of Select Private Cord Blood Banks, 2017 to Present	32
FIGURE 2.2:	U.S. Cord Blood Banks by Size of Inventory	36
FIGURE 2.3:	Proportion of Public, Private and Hybrid Banks in U.S.	40
FIGURE 2.4:	Percent Share of Parents of Newborns Storing Cord Blood by Country/Region	41
FIGURE 2.5:	Cord Blood Revenues for Companies, 2017 to Present	44
FIGURE 3.1:	Percent Share of AABB Accredited Cord Blood Facilities by Country	49
FIGURE 5.1:	Separation of Buffy Layer	55
FIGURE 5.2:	PrepaCyte-CB	56
FIGURE 5.3:	Hetastarch (HES)	58
FIGURE 5.4:	AutoXpress II	59
FIGURE 5.5:	SEPAX 2	59
FIGURE 5.6:	Plasma Depletion (PD) Method (MaxCell Process)	60
FIGURE 5.7:	Density Gradient Separation of Cord Blood	61

FIGURE 5.8: Early-Stage HSC Recovery from Cord Blood by Technologies	62
FIGURE 5.9: Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood by Technologies	63
FIGURE 5.10: Late-Stage HSC Recovery from Cord Blood by Technologies	64
FIGURE 5.11: HSC (CD45+) Recovery Post Process from Whole Blood by Technologies	65
FIGURE 5.12: Days to Neutrophil Engraftment by Technology	66
FIGURE 5.13: Difference in TNC Recovery among Anticoagulants	67
FIGURE 5.14: Type of Anticoagulant and Cell Recovery Volume	68
FIGURE 5.15: Percent Cell Recovery by Sample Size	69
FIGURE 5.16: TNC Viability by Time Taken for Transport	70
FIGURE 5.17: Difference in Recovery of Viable TNC after Thawing	71
FIGURE 5.18: CD34+ Cell Count, CFU and Cell Apoptosis by Cryoprotectants	72
FIGURE 5.19: The Number of Stored and Transplanted CB Units in Korea-CORD by TNC	73
FIGURE 5.20: Number of Stored and Shipped CB Units and Utilization Rate by TNC Count	74
FIGURE 6.1: Number of Cord Blood Clinical Trials as Reported in PubMed.gov (2000 to Present)	79
FIGURE 6.2: Number of Cord Blood Clinical Trials by Geography	80
FIGURE 6.3: Number of Cord Blood Clinical Trials by Study Type	81
FIGURE 6.4: Number of Cord Blood Clinical Trials by Study Phase	82
FIGURE 6.5: Number of Cord Blood Clinical Trials by Funder Type	83
FIGURE 6.6: Percent Share of Indications in Children tested in Clinical Trials	84
FIGURE 6.7: Percent Share of Diseases in Ongoing Clinical Trials using Cord Blood Cells	91
FIGURE 6.8: Percent Share of Diseases in Clinical Trials using MSCs from Cord Tissue	92
FIGURE 6.9: Number of Cord Tissue-Based Clinical Trials by Geography as of June 2021	94
FIGURE 6.10: Cord Tissue-Based Clinical Trials by Study Phase	95
FIGURE 6.11: Cord Tissue-Based Clinical Trials by Funder Type	96
FIGURE 6.12: Wharton's Jelly-Based Clinical Trials by Study Phase	98
FIGURE 6.13: Number of Published Scientific Papers on UCB, 2000 to Present	107
FIGURE 6.14: Number of Published Scientific Papers on Cord Tissue, 2000 to Present	108
FIGURE 6.15: Number of Published Scientific Papers on Wharton's Jelly, 2000 to Present	109
FIGURE 6.16: Number of Published Scientific Papers on CB Expansion, 2000 to Present	110
FIGURE 7.1: Percent of Expectant Parents Who Have Heard About Cord Blood Banking	112
FIGURE 7.2: Undecided Expectant Parents about Cord Blood Banking	113
FIGURE 7.3: Brand Name Recognition of Cord Blood Banks by Expectant Parents	113
FIGURE 7.4: Factors Influencing the Choice of a Cord Blood Bank	114
FIGURE 8.1: Distribution of Cell Sources in HCTs as Reported in Be The Match	115
FIGURE 8.2: Comparisons of Cord Blood to other Allograft Sources	116
FIGURE 8.3: Major Indications for HTC in the U.S.	118
FIGURE 8.4: Trend in Allogeneic HCT in the U.S. by Recipient Age, 2000 to Present	119
FIGURE 8.5: Trends in Autologous HCT in the U.S. by Recipient Age, 2000 to Present	120
FIGURE 8.6: Transplants by Cell Source in Adult Patients, 2010 to Present	121
FIGURE 8.7: Transplants by Cell Source in Pediatric Patients <18 Years	122
FIGURE 8.8: Allogeneic HCTs by Cell Source Facilitated by NMDP/Be The Match	123
FIGURE 8.9: Unrelated Donor Allogeneic HCTs in Patients <18 Years/NMDP/Be The Match	124
FIGURE 8.10: Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity	125
FIGURE 8.11: Likelihood of Finding an Unrelated Cord Blood Unit for Patients <20 Years	126
FIGURE 8.12: Cumulative Probability of having a Stem Cell Transplant by Age	127
FIGURE 8.13: Cord Blood Utilization Trends	128
FIGURE 8.14: Number of UCB Donors Worldwide as Reported by WMDA, 2000 to Present	129
FIGURE 8.15: Number of CBUs Worldwide as Reported by WMDA, 2000 to Present	131

FIGURE 8.16: Unrelated BM, PBPC and CB Shipped, 2000-2020	133
FIGURE 8.17: Number of Umbilical Cord Blood Donors by Geography	134
FIGURE 8.18: Public Cord Blood Units Stored by Geography as Reported by the WMDA	135
FIGURE 8.19: Percent Shares of all Registered Donors by HLA Typing Level	136
FIGURE 8.20: Number of Searches Initiated by National Patients for Donors/CBU/Both	137
FIGURE 8.21: Types of CBU Shipments	138
FIGURE 8.22: TNC Count of CBUs Provided for Children and Adult Patients - Single	139
FIGURE 8.23: TNC Count of CBUs Provided for Children and Adult Patients - Multi	140
FIGURE 8.24: Percentage of HPC Products Provided for National and International Patients	141
FIGURE 8.25: Percentage of CB Units Provided for National and International Patients	142
FIGURE 8.26: Top Ten Countries with Number of Donors Listed per 10,000 Inhabitants	143
FIGURE 8.27: Percentage of HLA Typed CBUs Banked per Continent	144
FIGURE 8.28: Percentage TNC of Banked CBUs	145
FIGURE 8.29: Number of Donors per 10,000 Inhabitants by Select E.U. Countries	153
FIGURE 8.30: Global Exchange of Cord Blood Units, 2020	156
FIGURE 8.30: Global Shipments of CBUs by Geography in 2020	157
FIGURE 9.1: Percent Shares of Indications Targeted by UCB-MSCs in Clinical Trials	160
FIGURE 9.2: Percent Share of Clinical Indications using UCT-MSCs	162
FIGURE 9.3: Number of UCB Units Released by Cord Blood Registry by Application	164
FIGURE 10.1: Global Cord Blood Banking Market Revenue by Geography, 2020-2027	169
FIGURE 10.2: Percent Share of Global Cord Blood Banking Market Revenue by Geography	170
FIGURE 10.3: Percent Share of Global Cord Blood Banking Market, Public vs. Private	171
FIGURE 10.4: Percent Share of Cord Blood Banking Market by Indication	172
FIGURE 11.1: Growth of CBUs on the Be The Match Registry, 2001 to Present	179
FIGURE 11.2: Diversity of CBUs on Be The Match Registry	180
FIGURE 11.3: Number of CBUs on Be The Match Registry by Race and Ethnicity, 2020	181
FIGURE 11.4: Diversity of CBUs in Be The Match Registry	182
FIGURE 11.5: Cell Sources for Allogeneic HCT Facilitated by Be The Match Registry	183
FIGURE 11.6: Likelihood of a Matched Donor on Be The Match Registry by Ethnicity	184
FIGURE 11.7: Percent Recovery of Viable Cells by TotiCyte Technology	191
FIGURE 11.8: Growth in Number of New Transplant Patients Registered with the CIBMTR	194
FIGURE 11.9: New Patients per Year Registered with CIBMTR	195
FIGURE 11.10: Transplant Patients by Graft Source Registered with CIBMTR	196
FIGURE 11.11: Number of Cord Blood Units Stored in CBR and its Competitors	206
FIGURE 11.12: Key Figures of Sales Revenues and Gross Profits for Cordlife, 2014-2020	207
FIGURE 11.13: Cryo-Cell International's Revenues, 2016 to Present	211
FIGURE 11.14: Revenue and Gross Profit for GCBC, 2015-2020	219
FIGURE 11.15: Percent Share of Units Released by Indication	231
FIGURE 11.16: Key Figures of Sales Revenues & Gross Profits for Vita 34, 2014 to Present	236
FIGURE 11.17: Search Types in WMDA Search & Match Service, 2017 to Present	238

INDEX OF TABLES

TABLE 2.1: An Overview of Public Cord Blood Banks	27
TABLE 2.2: International Prices of Cord Blood Unit	28
TABLE 2.3: Prices of Cord Blood Units in NMDP Banks in the U.S.	29
TABLE 2.4: An Overview of Private Cord Blood Banks	31

TABLE 2.5: Profit Margins of Select Private Cord Blood Banks, 2017 to Present	32
TABLE 2.6: An Overview of Hybrid Cord Blood Banks	33
TABLE 2.7: World's 12 Largest Private Cord Blood Bank Operators	35
TABLE 2.8: Comparison of Three Largest Private Banks in U.S.	37
TABLE 2.9: List of Public, Private and Hybrid Cord Blood Banks in the U.S.	39
TABLE 2.10: Pricing for Storage in Commercial Banks	41
TABLE 2.11: Rate per Cord Blood Unit in the U.S. & Europe	42
TABLE 2.12: Cord Blood Revenues for Major Four Companies, 2017 to Present	44
TABLE 3.1: AABB Accredited Cord Blood Facilities	47
TABLE 3.2: Select FACT Accredited Cord Blood Facilities	50
TABLE 4.1: Indications for the Use of UCB-Derived Stem Cells for Transplantation	51
TABLE 4.2: Indications for the Use of UCB-Derived Stem Cells for Regenerative Medicine	54
TABLE 5.1: Advantages of PrepaCyte-CB	57
TABLE 5.2: Treatment Outcomes with PrepaCyte-CB	57
TABLE 6.1: U.S. Cord Blood Banks Supplying Cord Blood for Research	77
TABLE 6.2: Number of Cord Blood Clinical Trials by Geography	80
TABLE 6.3: Number of Cord Blood Clinical Trials by Study Type	81
TABLE 6.4: Number of Cord Blood Clinical Trials by Study Phase	82
TABLE 6.5: Number of Cord Blood Clinical Trials by Funder Type	83
TABLE 6.6: Percentage Share of Indications in Children Tested within Clinical Trials	84
TABLE 6.7: Cord Blood Clinical Trials involving Children	86
TABLE 6.8: Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Neurological Diseases	87
TABLE 6.9: Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Diabetes	87
TABLE 6.10: Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Cardiovascular Trials	88
TABLE 6.11: Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Auto-Immune Diseases	89
TABLE 6.12: Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Orthopedic Disorders	89
TABLE 6.13: Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Other Indications	90
TABLE 6.14: Clinical Trials using MSCs from Cord Tissue	92
TABLE 6.15: Number of Cord Tissue-Based Clinical Trials by Geography	93
TABLE 6.16: Number of Cord Tissue-Based Clinical Trials by Study Phase	94
TABLE 6.17: Number of Cord Tissue-Based Clinical Trials by Funder Type	95
TABLE 6.18: Select Cord Tissue-Based Clinical Trials by Commercial Entities, 2021	96
TABLE 6.19: Wharton's Jelly-Based Clinical Trials by Phase	97
TABLE 6.20: Wharton's Jelly-Based Clinical Trials by Commercial Entities	98
TABLE 6.21: Clinical Trials in Cord Blood-Derived Cell Expansion by Country, 2021	99
TABLE 6.22: Clinical Trials of Cell Expansion Studies by Stages in Development, 2021	100
TABLE 6.23: Twenty Clinical Trials involved in the Expansion of Cord Blood HSCs	100
TABLE 6.24: Cord Blood Expansion Approaches	106
TABLE 6.25: Select NIH Funding for Umbilical Cord Blood Research, 2019 to Present	111
TABLE 8.1: Comparisons of Cord Blood to other Allograft Sources in Transplantation	116
TABLE 8.2: Number of HCTs Performed in the U.S. as reported to CIBMTR by Disease	117
TABLE 8.3: No. of Cord Blood Units Available Worldwide According to WMDA, 1997-2020	130
TABLE 8.4: Unrelated BM, PBPC and CB Shipped, 1997-2020	132
TABLE 8.5: Total Number of Cord Blood Donors and Cord Blood Units by Country	146
TABLE 8.6: Number of Donors and CBUs by E.U. Country	154
TABLE 8.7: Number of Exports/Imports of Cord Blood Units (CBUs) in E.U.	155
TABLE 9.1: Clinical Trials using Cord Blood-Derived MSCs as Interventions	159
TABLE 9.2: Clinical Trials using Umbilical Cord Tissue (UCT) MSCs as Interventions	161

TABLE 10.1: Global Cord Blood Banking Market Revenue by Geography, 2020-2027	169
TABLE 11.1: AlphaCord's Pricing	175
TABLE 11.2: Growth of Cord Blood Units in the Be The Match Registry, 2001 to Present	178
TABLE 11.3: Diversity of CBUs on Be The Match Registry	179
TABLE 11.4: Number of CBUs on Be The Match Registry by Race and Ethnicity	180
TABLE 11.5: Cell Care's pricing for Processing and Storage	189
TABLE 11.6: Cells4Life's pricing for Cord Blood, Cord Tissue, Amnion and Placental Cells	190
TABLE 11.7: Cord Blood and Cord Tissue Products Released from Cells4Life	192
TABLE 11.8: Distribution of Transplant Patients by Graft Source Registered with CIBMTR	196
TABLE 11.9: Distribution of Transplant Patients by Indication Registered with CIBMTR	197
TABLE 11.10: Cord Blood Units Released from the Cord Blood Center Group	198
TABLE 11.11: Cordlife's Cord Blood Release Track Record	201
TABLE 11.12: Core23 Biobank's Processing and Storage Fees	204
TABLE 11.13: Cryo-Cell International's Revenues, 2016 to Present	211
TABLE 11.14: Cryo-Cell International's Pricing for Processing and Storage	212
TABLE 11.15: Allogeneic and Autologous Infusions by Indication Reported in EBMT	215
TABLE 11.16: GeneCell Internationals Prepaid Storage Plans	217
TABLE 11.17: Selected Financial Data for Global Cord Blood Corporation (GCBC)	218
TABLE 11.18: Inseption Lifebank's Pricing	221
TABLE 11.19: LifeCell International's Pricing	223
TABLE 11.20: Cost Comparison of MiracleCord versus Competitors	224
TABLE 11.21: Maze Cord Blood Laboratory's Payment Plans	225
TABLE 11.22: Comparison of Pricing of NECBB with Competitors	226
TABLE 11.23: Stem Cell Cryobank's Pricing for Processing and Storage	232

About BioInformant:

As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.

Serving market leaders that include Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data.

Learn more at www.BioInformant.com.

